Intellectual Property Watch; MSF Challenges Gilead Hepatitis C Patent In China
"According to the [Médecins Sans Frontières (MSF, Doctors Without Borders) press] release, “Gilead launched the sofosbuvir/velpatasvir
combination at a price of US$51,000 for a 12-week treatment course in
the United Kingdom, whereas the same treatment course is available for
as low as $286 in India from generic manufacturers. In China, this
combination was registered in May 2018, but Gilead has not yet announced
its price.”
Issues and developments related to Intellectual Property (e.g. Copyright, Fair Use, Patents, Trademarks, Trade Secrets) and Open Movements (e.g. Open Access, Open Data, Open Educational Resources (OER)), examined in the "Intellectual Property and Open Movements" and "Ethics of Data, Information, and Emerging Technologies" graduate courses I teach at the University of Pittsburgh School of Computing and Information. -- Kip Currier, PhD, JD
Showing posts with label Gilead Hepatitis C patent application in China. Show all posts
Showing posts with label Gilead Hepatitis C patent application in China. Show all posts
Subscribe to:
Posts (Atom)